Current Status
Currently nicotine receptor agonist research and drug designing is aimed for treatment of multiple diseases and disorders of the CNS.
Targacept has four drug candidates that are in clinical trials; AZD3480 (TC-1734) for ADHD which is currently in phase II clinical trials and AZD1446 (TC-6683) for Alzheimers disease in collaboration with AstraZeneca, TC-5619 for cognitive dysfunctions in schizophrenia and TC-5214 as an augmentation treatment for major depressive disorder (MDD) in subjects who did not respond adequately to first-line treatment with citalopram hydrobromide.
Memory pharmaceuticals with its partner Roche has one drug candidate, MEM 3454 (RG3487), a partial agonist of the nicotinic alpha-7 receptor, for Alzheimers disease.
Abbott Laboratories in partnership with NeuroSearch have two drug candidates in clinical trials, ABT-894, a selective α4β2 nicotine receptor agonist, for ADHD and ABT-560, a neuronal nicotinic receptor modulator, which was selected by Abbott in 2006 as a new development candidate for cognitive dysfunctions.
EnVivo pharmaceuticals has one drug candidate in clinical trials, EVP-6124, a selective α7 nicotine receptor agonist for Alzheimer’s disease and schizophrenia and one follow-up compound, EVP-4473, that has successfully completed pre-clinical development.
Read more about this topic: Nicotinic Agonist
Famous quotes containing the words current and/or status:
““I” is a militant social tendency, working to hold and enlarge its place in the general current of tendencies. So far as it can it waxes, as all life does. To think of it as apart from society is a palpable absurdity of which no one could be guilty who really saw it as a fact of life.”
—Charles Horton Cooley (1864–1929)
“The censorship method ... is that of handing the job over to some frail and erring mortal man, and making him omnipotent on the assumption that his official status will make him infallible and omniscient.”
—George Bernard Shaw (1856–1950)